High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2638-2645

  Beyer, J ^a   Kramar, A ^a   Mandanas, R ^a   Linkesch, W ^a   Greinix, A ^a   Droz, J P ^a   Pico, J L ^a   Diehl, A ^a   Bokemeyer, C ^a   Schmoll, H J ^a   Nichols, C R ^a   Einhorn, L H ^a   Siegert, W ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 10144262544     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2638     Document Type: Article

References (23)

1. Nichols CR, Tricot G, Williams SD, et al: Dose-intensive chemotherapy in refractory germ cell cancer - A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932-939, 1989
2. Nichols CR, Andersen J, Lazarus HM, et al: High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol. J Clin Oncol 10:558-563, 1992
3. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: Recent advances and future directions. J Natl Cancer Inst 84:1703-1709, 1992
4. Nichols CR, Rosti G: Dose-intensive therapy for germ cell neoplasms. Semin Oncol 19:145-149, 1992
5. Williams SD: High dose therapy in germ cell tumors: When, what, and how much. Ann Oncol 3:780-781, 1992
6. Broun ER, Nichols CR, Turns M, et al: Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 73:1716-1720, 1993
7. Droz JP, Pico JL, Biron P, et al: No evidence of a benefit of early intensified chemotherapy (HDCT) with autologous bone marrow transplantation (ABMT) in first line treatment of poor risk non seminomatous germ cell tumors (NSGCT): Preliminary results of a randomized trial. Proc Am Soc Clin Oncol 11:197, 1992 (abstr 602)
8. Motzer RJ, Gulati SC, Crown JP, et al: High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69:550-556, 1991
9. Broun ER, Nichols CR, Einhorn LE, et al: Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer 68:1513-1515, 1991
10. Linkesch W, Greinix HT. Höcker P, et al: Longterm follow up of phase I/II trial of ultrahigh carboplatin. VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc Am Soc Clin Oncol 12:232, 1993 (abstr 717)
11. Broun ER, Nichols CR, Kneebone P, et al: Long-term out-come of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124-128, 1992
12. Siegert W, Beyer J, Strohscheer I, et al: High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12:1223-1231, 1994
13. Droz JP, Pico JL, Ghosn M, et al: Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer 27:831-835, 1991
14. Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986
15. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Stat Assoc 78:427-434, 1983
16. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Treat Rep 50:163-170, 1966
17. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
18. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Horwich A, A'Hearn R, Gildersleve J, et al: Prognostic factor analysis of conventional dose salvage therapy of patients with metastatic non seminomatous germ cell cancer. Proc Am Soc Clin Oncol 12:232, 1993 (abstr 715)
20. Droz JP, Kramar A, Nichols CR, et al: Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: Assignment of prognostic groups. Proc Am Soc Clin Oncol 12:229, 1993 (abstr 704)
21. Motzer RJ, Geller NL, Tan CCY, et al: Salvage chemotherapy for patients with germ cell tumors. Cancer 67:1305-1310, 1991
22. Saxman SB, Nichols CR, Einhorn LE: Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: The Indiana University experience. J Clin Oncol 12:1390-1393, 1994
23. Droz JP, Kramar A, Pico JL: Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumors. Eur J Cancer 29A:818-821, 1993